Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-808-3 | CAS number: 110-85-0
Direct observations: clinical cases, poisoning incidents and other
Administrative data
- Endpoint:
- direct observations: clinical cases, poisoning incidents and other
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
Data source
Reference
- Reference Type:
- publication
- Title:
- Das Hirnstrombild vor und nach Kurzzeitbehandlung der Enterobiasis mit Piperazinderivaten.
- Author:
- Padelt B, Bruhn B, Nicolai A
- Year:
- 1 966
- Bibliographic source:
- Pediatr. Grenzgeb 5: 1-9
Materials and methods
- Study type:
- clinical case study
- Endpoint addressed:
- acute toxicity: oral
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- EEG was measured in children administered piperazine.
- GLP compliance:
- no
Test material
- Reference substance name:
- Piperazine
- EC Number:
- 203-808-3
- EC Name:
- Piperazine
- Cas Number:
- 110-85-0
- Molecular formula:
- C4H10N2
- IUPAC Name:
- piperazine
Constituent 1
Method
- Type of population:
- other: children
- Ethical approval:
- not specified
- Route of exposure:
- oral
- Reason of exposure:
- other: medical treatment
- Details on exposure:
- Piperazine has been used as an antihelmintic agent. 89 children that were adminitered doses of 90 -130 mg/kg piperazine in two doses during one day, were studied by EEG one day after treatment.
Results and discussion
- Clinical signs:
- No clinical signs
- Results of examinations:
- Results of examinations
16 of 89: no EEG changes
40 of 89: minor changes, within the normal range for age
33 of 89: Clear EEG changes, either epileptiform or increase in low-frequency waves.
in 16 of 89 also hyperventilation - provocation: in 13 of 16 clear increase in low-frequency waves and voltage increase. Allegedly no relationship with the type or seriousness of preceding infectious disease could be established.
Applicant's summary and conclusion
- Conclusions:
- Based on this report a LOAEL of 110 mg/kg for neurotoxicity in humans is proposed.
- Executive summary:
Piperazine has been used as an antihelmintic agent. 89 children that were adminitered doses of 90 -130 mg/kg piperazine in two doses during one day, were studied by EEG one day after treatment. In 33 of 89 children there were clear EEG changes, either epileptiform or increase in low-frequency waves. Based on this report a LOAEL of 110 mg/kg for neurotoxicity in humans is proposed.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
